Condition
MET Amplification clinical trials and research
As of November 12, 2026, Find a Trial lists 4 MET Amplification clinical trials that are recruiting, at sites in 12 countries (most in China (3), Australia (1), Canada (1)). By phase: Phase 2 (3), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 12Countries
Newest MET Amplification clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Osimertinib plus savolitinib for EGFR-mutated lung cancer with low-level MET amplification | Phase 2 | Qingdao | Recruiting | Jan 7, 2026 |
| Combining LMV-12 with Osimertinib for advanced lung cancer | Phase 1/2 | Changsha, Hunan | Recruiting | Oct 31, 2023 |
| Neoadjuvant immunotherapy for localized non-small cell lung cancer with rare mutations | Phase 2 | Guanzhou, Guangdong | Recruiting | Apr 5, 2023 |
| Treatment of advanced solid tumors with APL-101 for specific genetic mutations | Phase 2 | Los Angeles, California and 34 other locations | Recruiting | Jun 5, 2017 |
All recruiting trials (4)
-
Osimertinib plus savolitinib for EGFR-mutated lung cancer with low-level MET amplification
This trial tests whether adding savolitinib to osimertinib helps people with EGFR-mutant non-small cell lung cancer who became resistant to osimertinib and have low-level MET amplification.
-
Combining LMV-12 with Osimertinib for advanced lung cancer
This study is testing a new treatment combining LMV-12 with osimertinib to see if it can help people with advanced lung cancer who haven't responded to other treatments.
-
Neoadjuvant immunotherapy for localized non-small cell lung cancer with rare mutations
This study is testing if a combination of a new immunotherapy drug and chemotherapy can help people with localized lung cancer that has rare mutations by seeing if it can completely eliminate the tumor.
-
Treatment of advanced solid tumors with APL-101 for specific genetic mutations
This study is testing a new oral medication called APL-101 to see if it helps people with advanced lung cancer and other solid tumors that have certain genetic changes, especially those who haven't had success with standard treatments.
Related topics
Quick answers
How many MET Amplification clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 12 countries. The most sites are in China (3 trials), Australia (1 trial), Canada (1 trial), France (1 trial), Hungary (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.